Development of Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome with Pembrolizumab for Lung Squamous Cell Carcinoma

Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs). There are a few case reports of remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE) as an irAE. We herein report a 49-year-old Japanese man who developed acute-onset polyarthralgia and e...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2024/07/15, Vol.63(14), pp.2089-2096
Main Authors: Yoshida, Misaki, Hara, Satoshi, Nishioka, Ryo, Kobayashi, Takafumi, Murase, Yuya, Kimura, Hideharu, Mizushima, Ichiro, Kawano, Mitsuhiro
Format: Article
Language:English
Subjects:
Case reports
Edema
Immune checkpoint inhibitors
immune-related adverse events
Lung cancer
Lung carcinoma
Malignancy
Pembrolizumab
Remission
remitting seronegative symmetrical synovitis with pitting edema syndrome
Squamous cell carcinoma
Synovitis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs). There are a few case reports of remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE) as an irAE. We herein report a 49-year-old Japanese man who developed acute-onset polyarthralgia and edema of the back of both hands and bilateral lower legs after pembrolizumab administration for lung cancer. The patient's lung cancer was in complete remission, leading to the diagnosis of RS3PE induced by pembrolizumab rather than malignancy. When patients show RS3PE during ICI treatment, rheumatologists should consider the possibility of an irAE after excluding malignancy and systemic diseases.
ISSN:0918-2918
1349-7235
1349-7235
DOI:10.2169/internalmedicine.2475-23